Successful SARS-CoV-2 vaccine allergy risk management: The experience of a large Italian University Hospital

Review Allergy

Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis)

Priya Sellaturay et al.

Summary: This study reports 5 cases of confirmed PEG allergy, with most cases related to medications containing PEGs. Skin tests showed positive reactions in 3 cases, with 2 cases experiencing allergic reactions following the intradermal test.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper

Ludger Klimek et al.

Summary: In response to severe anaphylaxis cases following the COVID-19 vaccine BNT162b2, the EAACI has issued preliminary recommendations emphasizing the importance of understanding severe allergic reactions and not excluding mild to moderate allergic patients from vaccination. Healthcare practitioners must be adequately prepared to recognize and treat anaphylaxis, and a mandatory observation period post-vaccination is recommended.

ALLERGY (2021)

Add to Collection

Editorial Material Allergy

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Beatriz Cabanillas et al.

ALLERGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Tom Shimabukuro et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Allergy

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

Tiago Azenha Rama et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Immunology

Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines

John M. Kelso

VACCINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and December 2020

Kimberly H. Nguyen et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Allergy

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

Paul J. Turner et al.

Summary: Vaccines against COVID-19 are crucial for controlling the pandemic, with most adverse events being a result of immune response rather than allergic reactions. Although anaphylaxis is rare with vaccines, recent data on reactions to the Pfizer-BioNTech vaccine suggest a closer incidence rate of 1 in 200,000 doses. A global surveillance strategy led by allergists is proposed to gather data and provide evidence-based guidance to public health bodies and the public for reassurance.

WORLD ALLERGY ORGANIZATION JOURNAL (2021)

Add to Collection

Review Allergy